To provide evidence for this knowledge gap, we evaluated the sensitivity of breast cancer cells to a specific PRMT5 inhibitor, GSK3326595 that has been tested in a phase II clinical trial for breast cancer (NCT04676516)[31]. This evidence concerns the gene PRMT5 and breast cancer.